Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PTK787, Vatalanib
PTK787/ZK 222584 · 5 trials · 9 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Oxaliplatin/5-FU/LV and PTK787/ZK 222584 |
| 2 | PLACEBO_COMPARATOR | Oxaliplatin/5-FU/LV and placebo |
| PTK787/ZK 222584 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Vatalanib | DRUG | - |
| PTK787/ZK 222584 | DRUG | - |
| PTK787 | DRUG | Visudyne® + PTK787, 500 mg/day |
| Placebo | DRUG | Visudyne® + Placebo |
| PTK787/ZK 222584 (vatalanib) | DRUG | - |
Inclusion criteria: * Patients with metastatic colorectal cancer coming for initial chemotherapy * Documented metastatic colorectal cancer * WHO Performance Status of 0, 1, or 2 * Measurable tumors * Adequate hematologic status, liver and kidney function * Life expectancy greater than 12 weeks * Wr...
PTK787/ZK 222584, also known as vatalanib, is an investigational small molecule studied in oncology and related conditions. It has been evaluated in tumors, Von Hippel-Lindau disease, and wet age-related macular degeneration. It is being developed by Novartis AG (ticker NVS) and remains in clinical development.
PTK787/ZK 222584 has been studied for tumors and neoplasm metastasis, Von Hippel-Lindau disease including CNS and retinal hemangioblastoma, and wet age-related macular degeneration. These are investigational uses evaluated in clinical trials, not approved indications.
PTK787/ZK 222584 is developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the clinical trials evaluating the compound across oncology and ophthalmology indications.
PTK787/ZK 222584 is in Phase 1 development overall, with completed Phase 1 and Phase 2 trials. It is investigational and has not been approved by the FDA for any indication. No trials are currently active.
Completed trials include NCT00171587, a Phase 1 study of vatalanib with capecitabine in advanced cancer; NCT00138632, a Phase 1 study in wet age-related macular degeneration; and NCT00052013, a Phase 2 study in Von Hippel-Lindau related hemangioblastoma. All three trials are completed.
Yes, PTK787/ZK 222584 is also known as vatalanib, and is sometimes referred to simply as PTK787. These names refer to the same investigational small molecule developed by Novartis AG.